Side-effects of cidofovir in treating recurrent respiratory papillomatosis
Author Information
Author(s): Broekema Ferdinand I., Dikkers Frederik G.
Primary Institution: University Medical Center Groningen, University of Groningen
Hypothesis
Does the use of intralesional cidofovir increase the risk of laryngeal dysplasia in patients with recurrent respiratory papillomatosis?
Conclusion
The use of intralesional cidofovir does not increase the risk of laryngeal dysplasia.
Supporting Evidence
- Five patients developed dysplasia during treatment, which is 2.7% of the total.
- The incidence of spontaneous malignant degeneration of RRP is reported to be 2-3%.
- Intralesional cidofovir was administered to a total of 188 patients across 31 studies.
Takeaway
This study looked at how a medicine called cidofovir affects people with a throat disease. It found that using cidofovir doesn't make the disease worse.
Methodology
A qualitative review of 31 articles describing the use of intralesional cidofovir for patients with recurrent respiratory papillomatosis.
Potential Biases
Potential bias due to overlap in patient populations across studies.
Limitations
The follow-up period varied across studies, and some patients may have developed dysplasia after the follow-up period.
Participant Demographics
The study included 188 patients, with 104 adults and 84 children, comprising 98 males and 69 females.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website